We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
76
CALL
Lexicon Pharmaceuticals
LXRX
$1.04B
$3.64M 0.2%
2,735
+2,225
+436% +$27.4K
INDP icon
77
Indaptus Therapeutics
INDP
$231M
$3.59M 0.2%
299
+25
+9% +$321K
LAB icon
78
CALL
Standard BioTools
LAB
$311M
$3.58M 0.2%
3,312
-305
-8% -$3K
RDUS
79
CALL
DELISTED
Radius Health, Inc.
RDUS
$3.56M 0.2%
578
– –
ONCE
80
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$3.49M 0.19%
770
-632
-45% -$33.1K
FOLD
81
PUT
DELISTED
Amicus Therapeutics
FOLD
$3.39M 0.19%
3,499
+1,177
+51% +$10.6K
NVAX icon
82
CALL
Novavax
NVAX
$1.21B
$3.37M 0.19%
201
– –
BLUE
83
PUT
DELISTED
bluebird bio
BLUE
$3.31M 0.18%
40
+9
+29% +$8.99K
PSTV icon
84
Plus Therapeutics
PSTV
$25.9M
$3.19M 0.18%
6
+5
+500% +$4.69M
BDSI
85
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.96M 0.16%
617,496
+248,855
+68% +$1.41M
CEMP
86
DELISTED
Cempra, Inc.
CEMP
$2.95M 0.16%
94,763
+21,568
+29% +$600K
MNKD icon
87
PUT
MannKind Corp
MNKD
$1.21B
$2.94M 0.16%
4,062
-113
-3% -$1.39K
NWBO
88
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$2.94M 0.16%
917,942
+345,424
+60% +$1.66M
BLUE
89
DELISTED
bluebird bio
BLUE
$2.92M 0.16%
+3,509
New +$3.51M
RLYP
90
CALL
DELISTED
RELYPSA INC COM
RLYP
$2.92M 0.16%
1,030
+730
+243% +$15.7K
ONCS
91
DELISTED
OncoSec Medical Incorporated
ONCS
$2.9M 0.16%
5,565
+4,019
+260% +$3.02M
DVAX
92
DELISTED
Dynavax Technologies
DVAX
$2.9M 0.16%
120,000
-14,954
-11% -$375K
ALXN
93
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$2.9M 0.16%
152
– –
LAB icon
94
Standard BioTools
LAB
$311M
$2.86M 0.16%
264,196
-364,064
-58% -$3.58M
RVNC
95
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.85M 0.16%
834
+19
+2% +$659
ITCI
96
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.8M 0.15%
+520
New +$26.2K
PTCT icon
97
CALL
PTC Therapeutics
PTCT
$6.25B
$2.74M 0.15%
845
-316
-27% -$9.3K
ABBV icon
98
AbbVie
ABBV
$465B
$2.73M 0.15%
46,166
+22,650
+96% +$1.3M
CHL
99
CALL
DELISTED
China Mobile Limited
CHL
$2.71M 0.15%
481
– –
INO icon
100
CALL
Inovio Pharmaceuticals
INO
$84.7M
$2.68M 0.15%
333
+3
+0.9% +$239
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.